IDWeek 2025: Pre-Conference Coverage
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists.
In advance of the confernece, GlobalData highlighted highly
anticipated and noteworthy abstracts in this Pre-Conference Coverage report.
Scope
Indications, companies, and therapies discussed in the report are as follows:
• Respiratory syncytial virus (RSV)
•Moderna – mRNA-1345 (mRESVIA)
•Enanta Pharmaceuticals – EDP-323
• COVID-19
• Moderna – mRNA-1273.815 (Spikevax XBB.1.5)
• Invivyd – Pemivibart (Pemgarda)
• Complicated urinary tract infections (cUTIs)/acute pyelonephritis
• GSK and Spero Therapeutics – Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr)
• HIV
• ST Pharm – Pirmitegravir (STP0404)
• Nontuberculous mycobacteria (NTM)
• Paratek Pharmaceuticals – Omadacycline (Nuzyra)
• Epstein Barr virus (EBV)
• National Institute of Allergy and Infectious Diseases – EBV gp350 Ferritin Nanoparticle Vaccine Candidate adjuvanted with Matrix-M
• Complicated Staphylococcus aureus bacteremia (SAB)
• Armata Pharmaceuticals – AP-SA02
• Fungal Infections
• Elion Therapeutics – EL219
Reasons to Buy
This powerpoint-based deliverable highlights noteworthy conference abstracts, and the potential implications for your strategy, covering disease areas such as HIV, COVID-19, RSV, NTM, UTIs, and more.
Enanta Pharmaceuticals
Invivyd
GSK
Spero Therapeutics
ST Pharm
Paratek Pharmaceuticals
National Institute of Allergy and Infectious Diseases
Armata Pharmaceuticals
Elion Therapeutics
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports